A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT)

被引：13

作者：

Papadopoulos, Kyriakos P.

Crittenden, Marka R.

Johnson, Melissa Lynne

Lockhart, Albert C.

Moore, Kathleen N.

Falchook, Gerald Steven

Formenti, Silvia

Carvajal, Richard D.

Leidner, Rom S.

Naing, Aung

Rosen, Lee S.

Weiss, Glen J.

Iii, Wilson Caldwell

Gao, Bo

Paccaly, Anne

Stankevich, Elizabeth

Trail, Pamela

Fury, Matthew G.

Lowy, Israel

机构：

[1] START Ctr Canc Care, San Antonio, TX USA

[2] Providence Portland Med Ctr, Portland, OR USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Washington Univ, Sch Med St Louis, St Louis, MO USA

[5] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[6] Sarah Cannon Res Inst, Denver, CO USA

[7] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[8] Columbia Univ, Med Ctr, New York, NY USA

[9] Providence Canc Ctr, Earl A Chiles Res Inst, Portland, OR USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut Phase Program 1, Houston, TX USA

[11] Univ Calif Los Angeles, Div Hemato Oncol, Los Angeles, CA USA

[12] Canc Treatment Centers Amer, Goodyear, AZ USA

[13] REGENERON, Tarrytown, NY USA

[14] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[15] Regeneron Pharmaceut, Tarrytown, NY USA

[16] Regeneron, Basking Ridge, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.3024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3024

引用

页数：2